World Library  
Flag as Inappropriate
Email this Article

Serotonin receptor agonist

Article Id: WHEBN0007491352
Reproduction Date:

Title: Serotonin receptor agonist  
Author: World Heritage Encyclopedia
Language: English
Subject: Anticholinergic, Neuromodulation, Serotonin antagonist, Diisopromine, Acotiamide
Publisher: World Heritage Encyclopedia

Serotonin receptor agonist


A serotonin receptor agonist is a compound that activates serotonin receptors, in a manner similar to serotonin.

Non-selective agonists: Psilocin and DMT are serotonin analogs found in certain plants or mushrooms. These compounds act on a variety of serotonin receptor types.


  • 5-HT1A agonists 1
  • 5-HT1B agonists 2
  • 5-HT1D agonists 3
  • 5-HT1F agonists 4
  • 5-HT2A agonists 5
  • 5-HT2B agonists 6
  • 5-HT2C agonists 7
  • 5-HT4 agonists 8
  • 5-HT7 agonists 9
  • See also 10
  • References 11
  • External links 12

5-HT1A agonists

Azapirones such as buspirone, gepirone, and tandospirone are 5-HT1A agonists marketed primarily as anxiolytics, but also recently as antidepressants.

5-HT1B agonists

Triptans such as sumatriptan, rizatriptan, and naratriptan, are 5-HT1B receptor agonists that are used to abort migraine and cluster headache attacks.

5-HT1D agonists

In addition to being 5-HT1B agonists, triptans are also agonists at the 5-HT1D receptor, which contributes to their antimigraine effect caused by vasoconstriction of blood vessels in the brain.

5-HT1F agonists

LY-334,370 was a selective 5-HT1F agonist that was being developed by Eli Lilly and Company for the treatment of migraine and cluster headaches. Development is slow however due to toxicity detected in animal test subjects.

5-HT2A agonists

Psychedelic drugs like LSD, mescaline, and 2C-B, act as 5-HT2A agonists. Their action at this receptor is responsible for their "psychedelic" effects. Some of these drugs, act as agonists for other 5HT receptor subtypes. Not all 5-HT2A agonists are psychoactive.[1]

5-HT2B agonists

Drugs that act as agonists on this receptor are implicated in the progression of cardiac fibrosis.[2] Fenfluramine, Pergolide and Cabergoline have been withdrawn from some markets for this reason.[3] Some psychedelic drugs, including LSD and Psilocin, have been shown to activate this receptor directly.[4] MDMA has been reported to be both a potent direct agonist[5] and have an indirect effect by increasing plasma serotonin levels.[6]

5-HT2C agonists

Lorcaserin is a thermogenic and anorectic weight-loss drug which acts as a selective 5-HT2C agonist.

5-HT4 agonists

Cisapride and Tegaserod are 5-HT4 partial receptor agonist that were used to treat disorders of gastrointestinal motility. Prucalopride is a highly selective 5-HT4 receptor agonist that can be used to treat certain disorders of gastrointestinal motility. Other 5-HT4 agonists have shown potential to be nootropic type drugs via promoting acetylcholine release.

5-HT7 agonists

AS-19 (drug) is a 5-HT7 receptor agonist that has been used only in research.

See also


  1. ^ Aghajanian, M.D., G.K.; G.J. Marek, M.D., Ph.D. (1999). "Serotonin and Hallucinogens". Neuropharmacology 21 (2S): 16S.  
  2. ^ Hutcheson, J. D., Setola, V., Roth, B. L., & Merryman, W. D. (2011). Serotonin receptors and heart valve disease—it was meant 2B. Pharmacology & therapeutics, 132(2), 146-157.
  3. ^ Brea, J., Castro-Palomino, J., Yeste, S., Cubero, E., Párraga, A., Domínguez, E., & Loza, M. I. (2010). Emerging Opportunities and Concerns for Drug Discovery at Serotonin 5-HT2B Receptors. Current topics in medicinal chemistry, 10(5), 493-503.
  4. ^ Halberstadt, A. L., & Geyer, M. A. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 61(3), 364-381.
  5. ^ Hutcheson, J. D., Setola, V., Roth, B. L., & Merryman, W. D. (2011). Serotonin receptors and heart valve disease—it was meant 2B. Pharmacology & therapeutics, 132(2), 146-157.
  6. ^ Zolkowska, D., Rothman, R. B., & Baumann, M. H. (2006). Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. Journal of Pharmacology and Experimental Therapeutics, 318(2), 604-610.

External links

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.